Zoetis Inc. (NYSE: ZTS) experienced a sharp decline on Friday, with shares closing at $72.66, a drop of 5.97% for the day and 42.25% since the start of the year. The stock now sits just 1.7% above its 52-week low, reflecting investor concern over the company's reduced outlook and ongoing challenges in its core companion-animal business.
The company's second-quarter results, released earlier in the week, showed a mixed picture. Revenue remained essentially flat at $2.468 billion, while adjusted net income fell 1% to $781 million. However, adjusted diluted earnings per share (EPS) climbed 5% to $1.87, aided by a 6.2% reduction in diluted shares outstanding to 417.7 million. This buyback-driven boost was evident when calculating EPS based on the prior year's share count: $1.75, a 1.5% decline from the year-ago period.
Guidance Cut and Analyst Response
The more significant issue for investors is the company's revised 2026 guidance. Zoetis lowered its revenue midpoint by 6.1% to $9.22 billion and its adjusted EPS midpoint by 10.5% to $6.20. Organic revenue growth guidance swung from a +2% to +5% range to a -3% to -1% decline. This substantial reduction prompted a flurry of analyst actions. JPMorgan lowered its price target to $115 from $130, while UBS cut its target to $80 from $85. William Blair downgraded the stock to Market Perform. The consensus price target among 19 analysts stands at $104.19, a 43.4% premium to Friday's close, but the stock's trailing P/E ratio of 11.95 reflects the earnings boost from buybacks.
Capital Returns and Cash Flow Concerns
Zoetis has been aggressive in returning capital to shareholders, spending $1.159 billion to repurchase 11 million shares in the first half of the year, at an average price of $105.36 per share. However, the company's cash flow has not kept pace. Total capital returns, including dividends, amounted to $1.637 billion, exceeding operating cash flow of $1.056 billion. This shortfall led to a $974 million decrease in cash, leaving the company with $1.476 billion. With only $1.3 billion remaining under its buyback authorization, the cost of future repurchases may rise, potentially limiting the EPS support that investors have come to expect.
Weakness in Companion Animals
The decline in operating performance was concentrated in the U.S. companion-animal segment, where revenue fell 11% to $1.044 billion. Management attributed this to lower clinic visits and pet owner price sensitivity, as well as increased competition in dermatology, ongoing pressure on Simparica Trio, generic competition, and reduced Librela sales. International companion-animal revenue grew 8% on a reported basis and 5% organically, but this was not enough to offset the domestic weakness.
Contrast with Peers
Zoetis's struggles stand in contrast to its peers. IDEXX Laboratories (NASDAQ: IDXX) and Elanco Animal Health (NYSE: ELAN) both reported 10% revenue growth and raised their full-year outlooks. This divergence suggests that Zoetis may be facing company-specific challenges rather than a broad industry downturn. However, upcoming data from IDEXX's Investor Day on August 13 could provide clarity on whether the weakness is isolated or indicative of wider demand softness.
Market Context and Outlook
The stock's slide has brought it to levels not seen in a year, and the guidance cut has raised questions about the sustainability of its growth strategy. While buybacks have supported EPS, the underlying business is facing headwinds that may persist. Investors will be watching for further analyst revisions and any signs of stabilization in the companion-animal market. The company's ability to navigate these challenges will be key to restoring confidence in the stock.
